Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176
J Pediatr. 2024 Nov:274:114228.
doi: 10.1016/j.jpeds.2024.114228.
Epub 2024 Aug 28.
1 Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy. Electronic address: [email protected].
2 Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy.
3 Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, Catania, Italy.
4 Department of Pediatric Medicine, Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Center, Florence, Italy; SC di Pneumologia e UTSIR, AORN Santobono-Pausilipon, Naples, Italy; Paediatric Unit, Department of Translational Medical Sciences, Cystic Fibrosis Regional Reference Center, University of Naples Federico II, Naples, Italy.
5 Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Pediatric Cystic Fibrosis Regional center.
6 Paediatric Unit, Department of Translational Medical Sciences, Cystic Fibrosis Regional Reference Center, University of Naples Federico II, Naples, Italy.